Spondyloarthritis & psoriatic arthritis
Candidate Biomarkers for Response to Treatment in Psoriatic Disease
Authors' conclusion
Treatment with biologics and MTX affect serum CXCL10, MMP3, S100A8, ACP5, and CCL2 levels in patients with PsA. MMP3, S100A8, ACP5, and CXCL10 have potential use as serum biomarkers to predict response to treatment for PsA.
Study context
- Population
- Patients with PsA and cutaneous psoriasis without arthritis (PsC)
- Comparison
- Serum protein levels at 3- to 6-month follow-up vs baseline by treatment (tumor necrosis factor inhibitors (TNFi), IL-17i, methotrexate (MTX), untreated) in PsA and PsC
- Outcome
- Change in serum CXCL10, MMP3, S100A8, ACP5 and CCL2 with treatment; prediction of response to PsA treatment by baseline levels
- Follow-up
- 3- to 6-month follow-up
Methodological detailsbiobank serum samples, Luminex multiplex assay, logistic regression classification models
- Biobank serum samples
- Luminex multiplex assay
- Logistic regression classification models
Main finding
As reported in the abstract
Serum protein levels, follow-up vs baseline
- In PsA, TNFi reduced serum levels of all 5 proteins
- IL-17i increased ACP5 and CCL2
- MTX reduced MMP3
- No significant differences between treated or untreated PsC
- PsA TNFi vs Untreated PsA: P < 0.05
Further findings
Prediction of response to biologics in PsA by baseline levels
- Baseline CXCL10, MMP3, S100A8 and ACP5 had good predictive value (AUC)
- > 0.80
Original publication
Candidate Biomarkers for Response to Treatment in Psoriatic Disease. J Rheumatol. Published 1 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →